

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: ZUCKERMANN et al.

APPLICATION No.:

10/025,423

FILED:

12/18/01

For:

Oligonucleotide Transfection Screening Method

EXAMINER:

WESSENDORF, T.

ART UNIT:

1639

CONFIRMATION NO.:

6469

Supplemental Information Disclosure Statement After First Office Action but Before Final Action or Notice of Allowance–37 CFR 1.97(c)

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed *after* three months of the filing date of this application or *after* the mailing date of the first office action on the merits, whichever occurred last, but *before* the mailing date of either a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, whichever occurs first. The references listed on the enclosed Form PTO-1449 may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

\boxtimes	Copies	of	the	fol	lowing	references	are	enclosed:
	_				_			

All cited references

References marked by asterisks

☐ The following:

3. Effect of Information Disclosure Statement (37 CFR 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior

07/02/2003 SDENBOB1 00000026 10025423

01 FC:1806

180.00 OP

art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

- Applicant elects to pay the fee under 37 CFR 1.17(p) in the amount of \$180.00.
- ☑ The Commissioner is hereby authorized to charge any deficiency in fees to ensure timely submission of these papers to Deposit Account No. 50-2207.
- 5. Patent Term Adjustment (37 CFR 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted, Perkins Coie LLP

Date: 6-26-03

LeeAnn Gorthey

Registration No. 37,337

Correspondence Address:

Chiron Corporation
Intellectual Property – R440
P. O. Box 8097
Emeryville, CA 94662

Ph: 510 655-8730 Fax: 510 655-3542